Roth/MKM on Entrada Therapeutics (TRDA): 'we remain bullish on Entrada’s DMD programs'
Tweet Send to a Friend
Roth/MKM analyst Boobalan Pachaiyappan reiterated a Buy rating and $23.00 price target on Entrada Therapeutics (NASDAQ: TRDA)The analyst comments "As ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
